Announcements Trials
Browse Landscape

Phase

Phase 1 27Phase 2 18Phase 3 5Phase 1/2 5Phase 4 3

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 16Breast 5Tumor-Agnostic 3Gynecologic 3Thoracic 2Other solid neoplasm 1

Conditions

Neoplasms 3

Interventions

Drug Therapy 5Docetaxel 3Bevacizumab 3icotinib 2Vincristine 2Pemetrexed 2Misoprostol 2Genes, p53 2Gemcitabine 2Dexamethasone 2Carboplatin 2Aspirin 2pinaverium 1pentetreotide 1pembrolizumab 1pazopanib 1olaparib 1netupitant, palosentron drug combination 1nedaplatin 1lorlatinib 1durvalumab 1ceritinib 1atezolizumab 1Zoledronic Acid 1Water 1Vitamin E 1Vemurafenib 1Ultracet 1Triamcinolone 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Bevacizumab × Tumor-Agnostic × Clear all
NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

NCT04813913 2026-02-06

VASCATAQ

University Hospital, Rouen

Phase 4 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT01588184 2020-11-05

An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

Hoffmann-La Roche

Phase 4 Completed
95 enrolled 15 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡